1.
纳入本研究患者的基线特征
Characteristics of included patients
| Characteristic | No. of patients (n=112) | % |
| CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; EP: etoposide+cisplatin; NP: vinorelbine+cisplatin; TP: paclitaxel+cisplatin/ carboplatin; GP: gemcitabine+cisplatin/carboplatin; DP: docetaxel+cisplatin/ carboplatin. | ||
| Gender | ||
| Male | 77 | 68.8% |
| Female | 35 | 31.2% |
| Age (year) | ||
| Median age (range) | 64 (31-84) | |
| ≤65 | 62 | 55.4% |
| >65 | 50 | 44.6% |
| Histology | ||
| Squamous cell carcinoma | 37 | 33.0% |
| Adenocarcinoma | 56 | 50.0% |
| NSCLC unspecified | 19 | 20.0% |
| Clinical stage | ||
| Ⅲ | 48 | 42.9% |
| Ⅳ | 64 | 57.1% |
| ECOG PS scores | ||
| 0 | 69 | 61.6% |
| 1 | 36 | 32.1% |
| 2 | 7 | 6.2% |
| WBC count | ||
| Normal (≤10 000/mm3) | 76 | 67.9% |
| Pathologic (>10 000/mm3) | 36 | 32.1% |
| Baseline CYFRA21-1 (ng/mL） | ||
| Median (range) | 5.15 (1.53-95.62) | |
| Normal (≤3.2 ng/mL) | 40 | 35.7% |
| Elevated (>3.2 ng/mL) | 72 | 64.3% |
| Chemotherapy efficacy | ||
| CR | 1 | 0.9% |
| PR | 32 | 28.6% |
| SD | 44 | 39.3% |
| PD | 35 | 31.2% |
| Chemotherapy treatment | ||
| NP | 28 | 25.0% |
| GP | 17 | 15.2% |
| TP | 9 | 8.0% |
| DP | 49 | 43.8% |
| EP | 9 | 8.0% |
| Status at follow-up | ||
| Alive | 22 | 19.6% |
| Dead | 90 | 80.4% |